Corona Remedies IPO Subscription Status
Corona Remedies IPO subscribed over 9.91x on its second day till 5.00 PM on December 9, 2025.
- Corona Remedies IPO subscription QIB investors’ portion is 1.76 times, while NII subscribed 28.32 times, and RII investors subscribed 6.84 times.
- The company has received bids for 4,29,90,556 shares against 43,36,298 shares on offer on the second day of subscription.
- Corona Remedies IPO subscribed over 9.91x on its day 2.
- Corona Remedies IPO subscribed over 0.67x on its day 1.
About Corona Remedies Company
Founded in August 2004, Corona Remedies Limited is one of the leading pharmaceutical companies that is involved in manufacturing and selling products for women’s health, heart care, pain relief, urology, and other treatments. As per the report, among 30 others, Corona Remedies is the 2nd largest company in the Indian Pharmaceutical Market (“IPM”). Moreover, the company comprises a total of 88 R&D employees as of December 31, 2024.
The company offers 67 brands across various therapeutic areas, including women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory) as of December 2024. The company offers a pan-India presence with 2,598 medical representatives in 22 states. It comprises 2 manufacturing facilities located in the state of Gujarat.
Corona Remedies IPO GMP:
Corona Remedies IPO GMP was ₹262 as of Tuesday, 9 December 2025. That indicates the IPO is trading at ₹1324 with a ₹262 premium in the grey market against the issue price of ₹1062.
